ViiV Healthcare

@ViiVHC · United Kingdom · joined 05 Feb 2015

100% dedicated to preventing, treating & curing HIV #WeWontStop Follow @ViiVUS for US updates. Social Media Code of Conduct: https://t.co/wr2meAR90D

20 070Followers

998Following

12 119Posts total

2.6KViews on collected posts

Against accounts of the same size

5 posts from the last 90 days, next to the 10K–100K follower range. ordinary reach for its size, weaker reaction than most.

Median views502this account980median for 10K–100K

Reach, %2.50%this account3.27%median for 10K–100K

Engagement, %0.47%this account2.01%median for 10K–100K

Metric	This account	Median for 10K–100K	Ratio
Median views per post	502	980	0.51×
Reach (views ÷ followers)	2.50%	3.27%	0.76×
Engagement rate	0.47%	2.01%	0.23×

Others in this range → Compare with another account → How these benchmarks are built →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

44329 Jul

50231 Jul

643

55318 Aug

48126 Aug

Last 5 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.45%29 Jul

0.40%31 Jul

0.47%

1.81%18 Aug

1.04%26 Aug

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 2.01%.

What the audience does

Likes69.6%16 in total

Reposts26.1%6 in total

Bookmarks4.3%1 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Latest posts

#News for #Media and #Investors: Today we announced U.S. FDA approval of an HIV treatment option for young children living with HIV weighing at least 2kg. 👉 Find out more: https://t.co/qJu7ymj2um https://t.co/Nox9zCozYw 481 views · 5 likes · 0 reposts · 0 replies 26 Aug 2026 · Open on X →

For the second episode of our #HIV series we explore the evolution of HIV care and the person-centred approaches needed to help people live well and drive progress to end the epidemic. Read the second paid post on The New York Times site: https://t.co/Y2rkGnX85P https://t.co/0Rg 553 views · 7 likes · 3 reposts · 0 replies 18 Aug 2026 · Open on X →

Tackle HIV takes on Brazil…🏉 At #AIDS2026 in Rio de Janeiro, our @TackleHIV campaign joined inspiring voices like @gareththomas14 and community partners to show how sport, education, visibility and lived experiences can help shift attitudes on #HIV and drive real change. 💪 https 643 views · 1 likes · 2 reposts · 0 replies 31 Jul 2026 · Open on X →

#News for #Media and #Investors Open Forum Infectious Diseases has published results from a Phase 3 trial investigating an early switch to a long-acting HIV treatment following viral suppression on an oral two-drug regimen. Read more here: https://t.co/rmjFLDdUlY https://t.co 502 views · 2 likes · 0 reposts · 0 replies 31 Jul 2026 · Open on X →

#News for #Investors and #Media: At #AIDS2026 we’re presenting new clinical and real-world insights from across our long-acting portfolio and pipeline across #HIV treatment and prevention. Learn more 👉 https://t.co/hCvFtLB8iP https://t.co/ZjKDV0YZr6 443 views · 1 likes · 1 reposts · 0 replies 29 Jul 2026 · Open on X →